The Medical Letter on Drugs and Therapeutics
Budesonide (Uceris) for Ulcerative Colitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new extended-release formulation of the corticosteroid budesonide (Uceris – Santarus) for induction of remission in patients with mild to moderate ulcerative colitis.

STANDARD TREATMENT — In mild to moderate ulcerative colitis, an aminosalicylate such as mesalamine is generally used first for induction and maintenance of remission. Oral prednisone is effective for inducing remission in patients who have not responded to an aminosalicylate or have severe symptoms. Because of their adverse effects, corticosteroids are used systemically only until acute inflammation is under control, and then are tapered and discontinued. Rectally instilled aminosalicylates and corticosteroids are effective in the treatment of distal disease.1

BUDESONIDE — Budesonide is a synthetic corticosteroid with a strong affinity for glucocorticoid receptors ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Budesonide (Uceris) for Ulcerative Colitis
Article code: 1412b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian